Boehringer Ingelheim Kicks Off China Production of Key Diabetes Drug

Leading global biopharmaceutical company Boehringer Ingelheim announced the official kick-off of local production in China for its flagship diabetes drug Trajenta (linagliptin).

This represents a key step in the firm's strategy to deepen its footprint in China, marking a new leap from commercial operations towards deeper integration into the local industrial chain.

This local production plan will significantly enhance the supply stability and resilience of Trajenta in the Chinese market, further improving drug accessibility.

It will also drive equipment upgrades and capacity optimization at the company's Shanghai Human Pharma Production and Supply Site in the Zhangjiang area in Pudong, consolidating its strategic role as a major supply hub for the Asia-Pacific region.

Top executives from the company and representatives from the government witnessed the kick-off ceremony on Monday, a significant milestone in the company's 30-year history of cultivating the Chinese market.

President and CEO of Boehringer Ingelheim China Mohammed Tawil stated: "Initiating the Trajenta local production plan in Shanghai is a new milestone that underscores our strong commitment to deepening footprint in China.

"We will continue to leverage the speed, scale, and impact of the Chinese market, deepen our local roots to serve the world, and strive to be a practitioner of China's high-quality development and a driver of global innovation collaboration, ensuring innovative outcomes benefit patients and animal health faster."

Over the next five years, Boehringer Ingelheim plans to spend more than 5 billion yuan (US$70.4 million) on research and development (R&D) in China. The Human Pharma pipeline will focus on the areas of metabolism, inflammation, eye health, and oncology.

The Animal Health unit will also accelerate innovation in vaccine development, introducing globally leading innovative products that cover key species in both livestock and companion animals.

Over the past decades, the company has consistently increased investment in China, establishing a full-value-chain footprint encompassing early R&D, clinical development, manufacturing, commercialization, and external innovation.

While serving the local market, its Human Pharma and Animal Health production sites in China have evolved into supply hubs for the region and beyond.

The Human Pharma site supplies to multiple Asia-Pacific countries and regions, including Australia, New Zealand, and Singapore.

The Animal Health plant in Nanchang in Jiangxi Province has been upgraded to a global production site, currently supplying products to countries including Brazil and Argentina, and it is projected to supply over 5 billion poultry vaccine doses annually to more than 30 countries in the future.

At this new starting point, Boehringer Ingelheim will comprehensively upgrade its development strategy in China, accelerate the translation of R&D achievements, and integrate more openly into China's healthcare innovation ecosystem.